Loading clinical trials...
Loading clinical trials...
An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Conditions
Interventions
Elotuzumab
Pomalidomide
+1 more
Locations
55
United States
Winship Cancer Institute
Atlanta, Georgia, United States
Rush University Medical Center
Chicago, Illinois, United States
Investigative Clinical Research Of Indiana, Llc
Indianapolis, Indiana, United States
Beth Israel Comprehensive Cancer Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute.
Boston, Massachusetts, United States
Rochester General Hospital
Rochester, New York, United States
Start Date
March 18, 2016
Primary Completion Date
January 17, 2018
Completion Date
October 21, 2021
Last Updated
November 1, 2022
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions